FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number: 3235-0287 Estimated average burden									
	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Arnold Susan Elizabeth						2. Issuer Name and Ticker or Trading Symbol PhaseBio Pharmaceuticals Inc [PHAS]									(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officers (nice title					
(Last)	`	rst)	(Middle)	C.		3. Date of Earliest Transaction (Month/Day/Year) 07/12/2021									7	below)	Officer (give title below) VP, Preclinical and Chem				
1 GREA	T VALLEY											plicable									
(Street) MALVE	eet) ALVERN PA 19355					4. If Amendment, Date of Original Filed (Month/Day/Year) 07/14/2021									Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person Person					
(City)	(Si	tate)	(Zip)																		
		Tab	le I - Nor	า-Deriง	/ative	e Se	curit	ies A	cqu	ıired, I	Disp	osed o	f, or	Ben	eficiall	y Owned	I				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Execution Date,			, Transaction Disposed Code (Instr. 5)		rities Acquired (A) ed Of (D) (Instr. 3, 4			5. Amou Securitie Benefici Owned F	es ally Following	Form (D) o	n: Direct r Indirect estr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
										Code	v	Amount		(A) or (D)	Price	Transaci (Instr. 3	tion(s)			(11150: 4)	
Common	Stock			07/1	2/202	1				M ⁽¹⁾		4,519	9	A	\$1.74 27,760		,760		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transact Code (In 8)				6. Date Exercisal Expiration Date (Month/Day/Year			Ai Se Ui De		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	Owne Form: Direct or Ind (I) (Ins	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Dat Exe	te ercisable		xpiration ate	Title		Amount or Number of Shares						
Employee Stock Option (right to	\$1.74	07/12/2021			M			4,519	07/	12/2015 ⁽³	3) 0	7/12/2021	Com Sto		4,519	\$0	0		D		

Explanation of Responses:

- 1. Amended to correct the transaction code for common stock acquired through stock options exercised in a transaction on July 12, 2021.
- $2.\ Amended to add a transaction for the exercise of stock options on July 12, 2021.$
- ${\it 3. All shares underlying this option have vested.}\\$

Remarks:

/s/ John P. Sharp, Attorney-in-

09/03/2021

<u>fact</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.